Senores Pharmaceuticals Strong Financial & Operational Performance for Q4 & FY25

Ahmedabad, Gujarat, 16th May 2025 – Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its audited Financial Results for the 4th Quarter of FY25 ended 31st March 2025.

For FY25, Regulated Market Revenue stood at Rs. 244.8 crs, a growth of 69% on a Y-o-Y basis. EBIDTA for Regulated Market business stood at Rs. 101.9 crs, with EBITDA Margin of 38.4%.

Emerging Markets Revenue stood at Rs. 121.2 crs, a growth of 174% on a Y-o-Y basis. Emerging Markets EBITDA Margin stood at 7.0% for FY25.
In the regulated markets currently, company has;
22 Own commercial products
61 Approved ANDA products
51 Pipeline products with 28 CGT opportunity products
22 CDMO/CMO commercial products
69 CDMO/CMO pipeline products
For the emerging markets currently, company has;
285 Approved products
636 products under registration
Presence across more than 40 countries

Commenting on the results, Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited said, “We are pleased to report strong performance for FY25, driven by our strategy of developing niche products for Regulated Markets and expanding our CDMO/CMO operations. At the same time, we have continued to grow our presence and product portfolio in Emerging Markets. Our Total Income and Profit before Tax for FY25 have increased by 91% & 183% respectively on year-on-year basis, and we are optimistic about sustaining this momentum going forward.

We continued to make steady progress on our stated strategies. During the quarter, we expanded our portfolio in the Regulated Markets through acquisition of 14 ANDA’s from Dr. Reddy’s and 1 ANDA from Breckenridge Pharmaceuticals. A large part of this acquired ANDA basket has considerable government contract opportunities. Further, our CDMO/CMO segment is gaining traction and continued to scale up well. We have launched 1 new product in the CDMO/CMO segment during the quarter and have 69 products in pipeline.

Our shift in product portfolio and go-to-market strategies in the Emerging Markets business is beginning to give the desired results, which can be seen in the improvement in margin during the quarter. We have registered 48 new products across the Emerging Markets during Q4FY25, taking the total portfolio to 285 registered products.
Going forward, although the uncertainties due to the tariff situation in USA will have to be closely monitored, we believe we are well placed to navigate the same, given our USFDA-approved manufacturing facility in USA.
We will continue to focus on three key pillars going forward – Expansion of ANDA portfolio in Regulated Markets; Steady scale-up of CDMO/CMO segment in the Regulated Markets; and Portfolio expansion and profitability improvement in the Emerging Markets.”